Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd Michael Bauer et al. · The Lancet Oncology · 2018

Cited by 790 works. doi:10.1016/s1470-2045(18)30649-1

Authors

References